Inhibikase Therapeutics (IKT) Asset Utilization Ratio (2021 - 2024)
Inhibikase Therapeutics (IKT) has 4 years of Asset Utilization Ratio data on record, last reported at 0.0 in Q3 2024.
- On a quarterly basis, Asset Utilization Ratio fell 100.0% to 0.0 in Q3 2024 year-over-year; TTM through Sep 2024 was 0.0, a 100.0% decrease, with the full-year FY2023 number at 0.01, up 260.65% from a year prior.
- Asset Utilization Ratio reached 0.0 in Q3 2024 per IKT's latest filing, down from 0.01 in the prior quarter.
- Over the last five years, Asset Utilization Ratio for IKT hit a ceiling of 0.14 in Q1 2021 and a floor of 0.0 in Q3 2024.
- A 4-year average of 0.03 and a median of 0.02 in 2024 define the central range for Asset Utilization Ratio.
- Peak YoY movement for Asset Utilization Ratio: surged 715.42% in 2023, then plummeted 100.0% in 2024.
- Tracing IKT's Asset Utilization Ratio over 4 years: stood at 0.07 in 2021, then plummeted by 93.43% to 0.0 in 2022, then surged by 248.72% to 0.02 in 2023, then tumbled by 100.0% to 0.0 in 2024.
- Business Quant data shows Asset Utilization Ratio for IKT at 0.0 in Q3 2024, 0.01 in Q2 2024, and 0.02 in Q1 2024.